Longs, disappointing we missed 3Q, but MRNA is oversold on the news. This is only 3d time MRNA reported since launching 1st commercial product. Here's the reality:
- 3Q $5B revenue & $7 EPS is still increasing tread over last 2Qs.
- 4Q will continue upward tread.
- MRNA has $17B in Advance Purchase Orders for 2022.
- MRNA reported record Cash on Hand.
- MRNA grabbed 40 institutions last week. We now have 1414 (+97 since 1 OCT).
GL LONGS, disappointing dip, but as an investor, I'm accumulating next week...
精彩评论